Auxilium Pharmaceuticals (Nasdaq: AUXL ) is expected to report Q4 earnings around Feb. 10. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Auxilium Pharmaceuticals's revenues will expand 135.3% and EPS will shrink -792.0%.
The average estimate for revenue is $172.5 million. On the bottom line, the average EPS estimate is $1.73.
Last quarter, Auxilium Pharmaceuticals chalked up revenue of $71.0 million. GAAP reported sales were 6.5% higher than the prior-year quarter's $66.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.21. GAAP EPS were -$0.21 for Q3 versus -$0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.7%, 200 basis points worse than the prior-year quarter. Operating margin was -15.1%, 880 basis points worse than the prior-year quarter. Net margin was -14.8%, 870 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $394.3 million. The average EPS estimate is $1.62.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 131 members out of 185 rating the stock outperform, and 54 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Auxilium Pharmaceuticals a green thumbs-up, and 25 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $26.18.